New research indicates that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Findings released in a prominent medical journal demonstrates that while overweight individuals often shed substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"People purchasing these treatments must be cognizant of the danger of quick rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about one and a half years.
Analyzing Approaches
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods.
The team note that people who shed pounds through diet and exercise usually see a less rapid creep back—approximately 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Nutrition scientists propose the mechanism of the jabs accounts for the heightened rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means appetite is no longer kept in check, making overeating far more likely."
A Chronic Condition?
Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts argue that, considering the likelihood of relapse, the treatment should be considered life-long.
This view is reinforced by pharmaceutical companies, who say that the results "highlight the persistent nature of excess weight," similar to managing diseases like high blood pressure.
Patient Testimonies
Users who have discontinued the medication explain a intense return of cravings.
"I experienced a switch that goes on and you become starving," described one woman.
This challenge is compounded if users have not established permanent dietary or behavioural changes during treatment.
Widespread Use
Survey data show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Finally, researchers emphasize that while these medications are powerful tools for weight loss, they are not a standalone cure and long-term success likely depends on combined behavioural support.
